Lupin has launched Rufinamide Oral Suspension, 40 mg/mL to market a generic equivalent of Banzel Oral Suspension, 40 mg/mL of Eisai Inc. Rufinamide Oral Suspension (RLD Banzel) had estimated annual sales of $72 million in the U.S.
Earlier, the company had launched Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100 mg/mL) Multiple-dose Vials, after Lupin’s alliance partner Caplin Steriles (Caplin) received an approval for its ANDA from the United States Food and Drug Administration (USFDA).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
